

ASX RELEASE

Results of Scheme Meeting

Melbourne, Australia, 15 July 2020: [Sienna Cancer Diagnostics Limited \(ASX: SDX\)](#) (“Sienna” or “the Company”) held a meeting of shareholders today, Wednesday 15 July 2020 at 11.00am (AEST), to consider and vote on the Scheme of Arrangement in relation to the proposed acquisition of all the shares in Sienna by BARD1 Life Sciences Limited (**Scheme**).

Sienna is pleased to announce that Sienna Shareholders voted overwhelming in favour of the Scheme - satisfying the shareholder approval head count and approval requirements for the Scheme.

The Scheme remains subject to the approval of the Federal Court of Australia.

Information required to be disclosed by Sienna in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the *Corporations Act 2001 (Cth)* is attached.

ENDS.

For Further Information, please contact:

Carl Stubbings, CEO & Managing Director
Sienna Cancer Diagnostics Ltd
cstubbings@siennadiagnostics.com.au
+61 3 8288 2141

The release of this announcement was authorised by Tony Di Pietro, Company Secretary.

About Sienna Cancer Diagnostics Ltd.

Sienna is a medical technology company that develops and commercialises diagnostic tests to assist in the early and accurate diagnosis of cancer, enabling improved treatment and patient outcomes. Sienna’s first product, hTERT, a test that aids in the diagnosis of bladder cancer, has been launched and is being commercialised through a growing network of distribution partners globally.

Sienna entered the global liquid biopsy market in 2019 via the strategic acquisition of a “Molecular Net” technology called SIEN-NET™. The first commercial embodiment of SIEN-NET is EXO-NET™, which has been specifically designed to purify a patient sample for cancer-associated exosomes.

The Company recently announced the signing of an exclusive worldwide licence agreement with the University of Adelaide to develop and commercialise a unique cancer probe, SubB2M, which binds to a unique sugar molecule only present in human cancers and can detect its presence in the serum of cancer patients. SubB2M has the potential to detect cancer in a range of testing modalities such as liquid biopsies, immunoassays, circulating tumor cell assays and PET imaging.



SIENNA CANCER DIAGNOSTICS LIMITED

RESULT OF ANNUAL GENERAL MEETING (ASX REPORT)

SCHEME OF ARRANGEMENT MEETING
Wednesday, 15 July, 2020

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Poll (Manner in which votes were cast in person or by proxy on a poll (where applicable) on a poll at the meeting)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1	THAT, PURSUANT TO AND IN ACCORDANCE WITH SECTION 411 OF THE CORPORATIONS ACT 2001 (CTH), THE SCHEME, THE TERMS OF WHICH ARE CONTAINED AND MORE PARTICULARLY DESCRIBED IN THE SCHEME BOOKLET (OF WHICH THIS NOTICE OF SCHEME MEETING FORMS PART) IS APPROVED, WITH OR WITHOUT ANY MODIFICATION OR CONDITIONS REQUIRED BY THE FEDERAL COURT OF AUSTRALIA, AND SUBJECT TO APPROVAL OF THE SCHEME BY THE FEDERAL COURT OF AUSTRALIA, THE BOARD OF DIRECTORS OF SIENNA IS AUTHORISED TO IMPLEMENT THE SCHEME WITH ANY SUCH MODIFICATIONS OR CONDITIONS.	N	207,173,248 91.92%	341,668 0.15%	17,868,768 7.93%	0	227,631,625 99.85%	341,668 0.15%	0	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item